These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 4179303)

  • 1. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies.
    Pinchera A; Liberti P; Martino E; Fenzi GF; Grasso L; Rovis L; Baschieri L; Doria G
    J Clin Endocrinol Metab; 1969 Feb; 29(2):231-8. PubMed ID: 4179303
    [No Abstract]   [Full Text] [Related]  

  • 2. The changes of serum titers of thyroid antibodies in patients of Graves' disease with hyperthyroidism after treatments with antithyroid drugs.
    Huang CS; Tseng FY; Chang TC; Chang CC; Chen FW; Torng JK
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1983 Nov; 16(4):277-82. PubMed ID: 6202467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large doses of radioiodide in Graves' disease: effect on ophthalmopathy and long-acting thyroid stimulator.
    Pequegnat EP; Mayberry WE; McConahey WM; Wyse EP
    Mayo Clin Proc; 1967 Dec; 42(12):802-11. PubMed ID: 4169552
    [No Abstract]   [Full Text] [Related]  

  • 4. The evolution of the ophthalmopathy during antithyroid drug therapy and its relationship with serum thyroglobulin and antithyroglobulin antibody in patients with Basedow's disease.
    Bromberg N; Werner RS; Sgarbi JA; Werner MC; Romaldini JH
    Exp Clin Endocrinol; 1991 May; 97(2-3):354-7. PubMed ID: 1717300
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoimmune response to the antithyroid and 131-I therapy of hyperthyroidism.
    Takó J; Bános C
    Endokrinologie; 1971 Apr; 57(3):400-4. PubMed ID: 4103579
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse.
    Gong ST; Chao IM
    J Formos Med Assoc; 1991 Dec; 90(12):1155-62. PubMed ID: 1724781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Tripterygium glycosides on thyroid function and auto-antibody in patients with Graves disease].
    Tang L; Liang ZQ; Su K
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Apr; 23(4):294-5. PubMed ID: 12764916
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroid responsiveness in Gravesian ophthalmopathy.
    Mendelsohn LV; Mouton DE; Goldzieher JW
    Arch Intern Med; 1972 Jul; 130(1):119-20. PubMed ID: 5067864
    [No Abstract]   [Full Text] [Related]  

  • 10. Radioimmunological studies on the long-acting thyroid stimulator.
    Pinchera A; Rovis L; Grasso L; Liberti P; Martino E; Fenzi GF; Baschieri L
    Endocrinology; 1970 Aug; 87(2):217-25. PubMed ID: 4193237
    [No Abstract]   [Full Text] [Related]  

  • 11. Preventing Graves' ophthalmopathy.
    Wiersinga WM
    N Engl J Med; 1998 Jan; 338(2):121-2. PubMed ID: 9420345
    [No Abstract]   [Full Text] [Related]  

  • 12. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
    Wils JA; Kloppenborg PW
    J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
    [No Abstract]   [Full Text] [Related]  

  • 13. Antithyroid drugs in practice.
    Vanderlaan WP
    Mayo Clin Proc; 1972 Dec; 47(12):962-5. PubMed ID: 4117991
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship between the long-acting thyroid stimulator and circulating thyroid antibodies in Graves' disease.
    Pinchera A; Liberti P; De Santis R; Grasso L; Martino E; Baschieri L
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1758-60. PubMed ID: 6072765
    [No Abstract]   [Full Text] [Related]  

  • 15. No prognostic value of thyroid autoantibodies changes during and after methimazole therapy in patients with Graves' disease.
    Lattanzi V; Ciampolillo A; Vincenti C; Giorgino R
    Boll Soc Ital Biol Sper; 1985 Apr; 61(4):507-13. PubMed ID: 3840026
    [No Abstract]   [Full Text] [Related]  

  • 16. Iodine distribution in thyroid tissue taken from hyperthyroid patients treated with Lugol's solution or carbimazole.
    Etling N
    Rev Eur Etud Clin Biol; 1971; 16(7):662-7. PubMed ID: 4107371
    [No Abstract]   [Full Text] [Related]  

  • 17. Current concepts in management of thyroid disease.
    DeGroot LJ
    Med Clin North Am; 1970 Jan; 54(1):117-30. PubMed ID: 4189143
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thyrotoxicosis].
    Nagata I
    Naika Hokan; 1970 Dec; 17(12):459-77. PubMed ID: 4099951
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.